EXPAREL revenue grew 3% while company divested iovera and expanded insurance coverage.

In early August 2026, Pacira BioSciences reported positive two-year Phase 1 data for its investigational gene therapy PCRX-201 for moderate-to-severe knee osteoarthritis, showing it was well tolerated with exploratory improvements in pain, stiffness, and function, while also advancing Phase 2 enrollment and confirming a successful scale-up to a commercial-ready manufacturing process. PCRX-201 is the first gene therapy for knee osteoarthritis to pair these kinds of sustained clinical results...

Why Pacira BioSciences Stock Is Back in Focus Pacira BioSciences (PCRX) is drawing fresh attention after publishing two year Phase 1 data for its PCRX-201 gene therapy in knee osteoarthritis, along with recent updates on revenue, profitability, guidance, and manufacturing. See our latest analysis for Pacira BioSciences. The recent PCRX-201 update lands after a sharp 1-day share price return decline of 9.96% and a softer 7-day share price return of 7.79%. Pacira BioSciences still shows a...

PCRX beats Q2 earnings estimates as higher product sales boost revenues, with Exparel demand and portfolio momentum supporting growth despite a guidance cut.

Moby summary of Pacira BioSciences, Inc.'s Q2 2026 earnings call

Pacira BioSciences Inc (PCRX) reports a 6% revenue increase, advances EXPAREL reimbursement, and completes iovera divestiture to sharpen focus on core pipeline.

Pacira BioSciences (NASDAQ:PCRX) reported second-quarter 2026 revenue growth, led by higher sales of its EXPAREL, ZILRETTA and iovera° products, while highlighting expanded payer coverage, pipeline progress and the completed sale of iovera° to Zimmer Biomet. Total second-quarter revenue rose 6% fro

Pacira (PCRX) delivered earnings and revenue surprises of +14.06% and +1.01%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?